Recent Analysts’ Ratings Changes for Axsome Therapeutics (AXSM)

A number of research firms have changed their ratings and price targets for Axsome Therapeutics (NASDAQ: AXSM):

• 1/24/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 1/21/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
• 1/13/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 1/13/2025 – Axsome Therapeutics had its price target raised by analysts at Truist Financial Co. from $150.00 to $180.00. They now have a “buy” rating on the stock.
• 1/6/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 12/31/2024 – Axsome Therapeutics had its price target lowered by analysts at Mizuho from $124.00 to $122.00. They now have an “outperform” rating on the stock.
• 12/31/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 12/30/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.
• 12/12/2024 – Axsome Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $121.00 price target on the stock.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $102.69 on Tuesday. The stock’s 50-day moving average is $92.64 and its 200-day moving average is $90.15. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $105.64. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The stock has a market cap of $4.98 billion, a P/E ratio of -15.73 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the prior year, the business posted ($1.32) earnings per share. Equities research analysts anticipate that Axsome Therapeutics, Inc. will post -4.73 earnings per share for the current year.

Institutional Trading of Axsome Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in shares of Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after acquiring an additional 27,534 shares in the last quarter. PDT Partners LLC bought a new stake in Axsome Therapeutics in the third quarter worth approximately $1,052,000. Pallas Capital Advisors LLC bought a new stake in Axsome Therapeutics in the fourth quarter worth approximately $2,237,000. Captrust Financial Advisors acquired a new position in Axsome Therapeutics in the third quarter valued at approximately $514,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Axsome Therapeutics by 71.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock worth $1,234,000 after buying an additional 5,737 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.